Company Profile

Stony Brook Biotechnology, LLC was formed by Dr. Anil Dhundale to develop and commercialize a diagnostic test based on proprietary biomarkers discovered at Stony Brook University. The commercial goal is to enable microsphere-based transcript profiling of blood platelets for the diagnosis of Essential Thrombocythemia (ET) that causes high platelet levels. Funding for this project, “Diagnostic Assay for Thrombocytosis,” at the small business startup, Stony Brook Biotechnology, LLC, and at Stony Brook University, was provided through a $178,894 STTR (Small Business Technology Transfer Program) grant, with Dr. Dmitri Gnatenko as Principal Investigator (Sept 2010-2011). The diagnosis of ET by exclusion, currently the only available method, is costly, nonspecific and time consuming, and invasive testing must be performed to rule out other disease causing high platelet levels. Based on literature reports on incidence, it is estimated that the number of people with a confirmed high platelet count in the U.S. is between 100,000and 500,000 annually, creating a roughly estimated, fully penetrated, U.S. market opportunity between $20 million and $100 million annually. Stony Brook Biotechnology’s value proposition is in time, money and discomfort saved versus the current standard of diagnosis by exclusion. The company’s longer-term vision is to find commercial application of other blood-related biomarker assays from research at Stony Brook Univ